[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652624":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":26,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":26,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":26},{"fullName":5,"class":6},"Clinica Alemana de Santiago","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Subcutaneous methadone","EXPERIMENTAL","Patients receive subcutaneous methadone for postoperative analgesia following cesarean delivery under neuraxial anesthesia as part of a multimodal analgesia regimen.",[13],"Drug: Methadone 0.15 mg\u002Fkg",{"label":15,"type":16,"description":17,"interventionNames":18},"Intrathecal morphine","ACTIVE_COMPARATOR","Patients recieve intrathecal preservative-free morphine for postoperative analgesia following cesarean delivery under neuraxial anesthesia as part of a multimodal analgesia regimen.",[19],"Drug: morphine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Methadone 0.15 mg\u002Fkg","Subcutaneous methadone administered for postoperative analgesia following cesarean delivery under neuraxial anesthesia.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"morphine","Intrathecal morphine administered during neuraxial anesthesia for postoperative analgesia following cesarean delivery.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"JAVIERA VARGAS, MD, MSc","CONTACT","+56957383772","jpvargasz@gmail.com",{"type":38,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100652624","subcutaneous-methadone-for-cesarean-analgesia-a-non-inferiority-study-using-qor-10-100652624",false,"NCT07777029","Subcutaneous Methadone for Cesarean Analgesia: a Non Inferiority Study Using QoR-10","Subcutaneous Methadone for Cesarean Analgesia: A Non-inferiority Study Using Quality of Recovery -10 Score.","SC-METH-CES","Inclusion Criteria:\n\n* Women aged 18-45 years\n* Singleton pregnancy at term (≥37 weeks of gestation)\n* Scheduled for elective cesarean delivery\n* Planned neuraxial spinal anesthesia\n* Ability to understand and complete the QoR-10 questionnaire\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Emergency cesarean delivery\n* Contraindication to neuraxial anesthesia\n* Known hypersensitivity or allergy to methadone or morphine\n* Chronic opioid use or opioid dependence","FEMALE","18 Years","45 Years",{"count":51,"type":52},128,"ESTIMATED","INTERVENTIONAL",[55],"NA","This study aims to evaluate whether subcutaneous methadone provides postoperative analgesia that is non-inferior to that achieved with intrathecal morphine in women undergoing cesarean delivery under neuraxial anesthesia. The primary outcome will be the quality of postoperative recovery, assessed using the QoR-10 score during the first 24 hours after surgery. Secondary outcomes will include postoperative pain intensity, opioid consumption, incidence of adverse effects, and maternal satisfaction.\n\nThis trial seeks to determine whether subcutaneous methadone could represent an alternative analgesic strategy within multimodal analgesia protocols for cesarean delivery.",[58],"Cesarean Section Pain",[60,61,62,63,64],"cesarean section","methadone","intratecal morphine","recovery","maternal satisfaction","NOT_YET_RECRUITING","2026-08-18",{"date":68,"type":69},"2026-08-20","ACTUAL",{"date":71,"type":52},"2026-08-21",{"date":73,"type":52},"2027-03-31",{"name":5,"class":6}]